Human reproduction最新文献

{"title":"High serum estradiol levels on the day of frozen blastocyst transfer are associated with increased early miscarriage rates in artificial cycles using transdermal estrogens.","authors":"Chloé Maignien, Timon Jobin, Mathilde Bourdon, Léa Melka, Louis Marcellin, Christelle Laguillier-Morizot, Ahmed Chargui, Catherine Patrat, Charles Chapron, Pietro Santulli","doi":"10.1093/humrep/deaf037","DOIUrl":"https://doi.org/10.1093/humrep/deaf037","url":null,"abstract":"<p><strong>Study question: </strong>Do serum estradiol (E2) levels on the day of frozen blastocyst transfer (FBT) affect pregnancy outcomes in hormonal replacement therapy (HRT) cycles using transdermal estrogens?</p><p><strong>Summary answer: </strong>E2 levels ≥313 pg/ml on the day of FBT are associated with increased early miscarriage rates (EMRs), but do not significantly impact the live birth rate (LBR).</p><p><strong>What is known already: </strong>E2 plays a crucial role in endometrial receptivity and placentation. The effect of serum E2 levels measured around the time of FBT in HRT cycles remains debated, with some studies indicating a negative impact of high E2 levels and others finding no significant difference. Currently, no studies focus exclusively on HRT cycles using transdermal estrogens, which are considered safer regarding thromboembolic complications.</p><p><strong>Study design, size, duration: </strong>This retrospective cohort study analyzed 2364 patients undergoing HRT-FBT cycles at a university hospital between January 2019 and December 2022. Each patient was included only once during the study period.</p><p><strong>Participants/materials, setting, methods: </strong>The study involved patients undergoing single autologous FBT under HRT with transdermal estrogens and vaginal micronized progesterone. Serum E2 levels were measured in the morning of the FBT at a single laboratory. Primary outcomes included the LBR, with secondary outcomes encompassing clinical pregnancy rates, EMRs, and neonatal outcomes (birth weight and term of delivery). Patients were categorized into three groups based on E2 levels: <25th centile (<122 pg/ml), between 25th and 75th centile (122-312 pg/ml), and >75th centile (≥313 pg/ml), and analyzed using univariate and multivariate logistic regression models.</p><p><strong>Main results and the role of chance: </strong>Of the 2364 patients, 590 were in the '<122 pg/ml' group, 1184 in the '122-312 pg/ml' group, and 590 in the '≥313 pg/ml' group. The median (interquartile range) E2 level in the entire study population was 195.3 pg/ml (122.1-312.8). The LBRs across the E2 level groups were 33.7%, 31.6%, and 31.0%. Crude and adjusted odds ratios (ORs) showed no significant differences in LBR between the '<122 pg/ml' and '≥313 pg/ml' groups compared to the '122-312 pg/ml' reference group (adjusted OR 0.9, 95% CI 0.72-1.14 and 0.9, 95% CI 0.69-1.09, respectively). The EMRs for the groups were 25.5%, 24.6%, and 30.3%, respectively. While crude analysis showed no differences between the groups, the multivariable analysis indicated that the '≥313 pg/ml' group had a significantly higher risk of early miscarriage compared to the reference group (adjusted OR 1.5, 95% CI 1.06-2.18). No significant differences were observed in clinical pregnancy rates or neonatal outcomes.</p><p><strong>Limitations, reasons for caution: </strong>The primary limitation is the study's retrospective design, which introduces risks of selecti","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semen quality and lifespan: a study of 78 284 men followed for up to 50 years","authors":"L Priskorn, R Lindahl-Jacobsen, T K Jensen, S A Holmboe, L S Hansen, M Kriegbaum, B S Lind, V Siersma, C L Andersen, N Jørgensen","doi":"10.1093/humrep/deaf023","DOIUrl":"https://doi.org/10.1093/humrep/deaf023","url":null,"abstract":"STUDY QUESTION Is semen quality associated with the lifespan of men? SUMMARY ANSWER Men with a total motile sperm count of >120 million could expect to live 2.7 years longer than men with total motile sperm count of >0–5 million. WHAT IS KNOWN ALREADY Male infertility and semen quality have been suggested to be markers of morbidity and thus mortality, but the role of underlying disease present at time of semen quality evaluation has not been thoroughly assessed. The aim of this study was to determine the association between semen quality and mortality, and to assess the impact of the health of the man prior to semen quality assessment. STUDY DESIGN, SIZE, DURATION The study was based on 78 284 men who had their semen quality assessed between 1965 and 2015 at the public semen analysis laboratory in the Copenhagen area, Denmark, due to reported couple infertility. Thus, the included men covered a wide range of semen quality. Semen quality assessment included semen volume, sperm concentration, and the proportion of motile and morphologically normal sperm, from which the total sperm count and the total motile sperm count were calculated. Utilizing the unique Danish national registers, follow-up of the men regarding all-cause mortality was performed with a median follow-up of 23 years (5–95th percentile: 8–45 years) during which 8600 deaths occurred, accounting for 11.0% of the total population. PARTICIPANTS/MATERIALS, SETTING, METHODS Life expectancy was calculated according to semen quality. Furthermore, the relative differences in mortality were estimated using Cox regression analyses and presented as hazard ratios (HRs) with 95% CIs. A more recent subpopulation of 59 657 men delivered semen samples between 1987 and 2015, a period in which information on educational level and diseases prior to semen sampling was available and adjusted for in Cox regression analyses. MAIN RESULTS AND THE ROLE OF CHANCE Men with a total motile count of >120 million could expect to live 80.3 years, compared to 77.6 years among men with total motile count of >0–5 million. In Cox regression analyses, all semen parameters were negatively associated with mortality in a dose–response manner both in the total population and the more recent subpopulation (P-trend for all semen parameters <0.001), and adjustment for educational levels and prior diagnoses did not change the estimates in the latter. Looking at total motile sperm count as an example, men with a total motile sperm count >120 million served as the reference, and the adjusted HRs for all-cause mortality in the more recent subpopulation were: azoospermia: 1.39, >0–5 million: 1.61, >5–10 million: 1.38, >10–40 million: 1.27, >40–80 million: 1.16, >80–120 million: 1.19, P-trend < 0.001. LIMITATIONS, REASONS FOR CAUTION The study was well-powered and included a unique database of results from semen analyses combined with register follow-","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"23 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spermatozoa as harbingers of mortality: the curious link between semen quality and life expectancy.","authors":"Robert John Aitken","doi":"10.1093/humrep/deaf027","DOIUrl":"https://doi.org/10.1093/humrep/deaf027","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A video clip detailing the patient journey on the day of oocyte retrieval in addition to the standard of care: a randomized controlled trial","authors":"Louise Dias, Peter De Loecker, Sarah Willems, Thomas M D’Hooghe, Joris Vriens, Karen Peeraer, Eline A F Dancet","doi":"10.1093/humrep/deaf033","DOIUrl":"https://doi.org/10.1093/humrep/deaf033","url":null,"abstract":"STUDY QUESTION Can a video clip detailing the patient journey decrease women’s anxiety on the day of their first oocyte retrieval? SUMMARY ANSWER The video clip does not affect women’s anxiety on the day of their first oocyte retrieval. WHAT IS KNOWN ALREADY IVF triggers anxious reactions in women and men, with peaks of anxiety on the day of (especially the first) oocyte retrieval as shown by reliable questionnaires and biomarkers of distress. Several trials showed that videos with preparatory information reduce women’s and men’s anxiety for out-patient procedures. STUDY DESIGN, SIZE, DURATION This monocentric open-label randomized controlled trial (RCT) randomized (computerized 1:1 allocation) 190 heterosexual couples about to start their first IVF cycle during a 24 months’ recruitment period (2018–2020). In addition to the standard of care offered to both the intervention group and the control group, the intervention group received a video clip, the day prior to their first oocyte retrieval, detailing the patient journey on the day of oocyte retrieval. After completion of the RCT, 35 additional couples were recruited as part of a qualitative process evaluation (QPE). PARTICIPANTS/MATERIALS, SETTING, METHODS Upon arrival at a private secondary care fertility centre in Belgium for their first oocyte retrieval, women and men independently filled out the State module of the ‘State-Trait Anxiety Inventory’ (STAI) and the ‘Infertility-Specific Distress Scale’ (IDS) and evaluated the novel intervention, if applicable. In addition, clinical and discontinuation outcomes were extracted from couples’ electronic medical records 24 months later. The data of 155 couples (76–79/group) were subjected to an intention-to-treat analysis. The 35 couples taking part in the QPE filled out two questionnaires assessing knowledge and, if applicable, took part in an in-depth interview on their experience watching the video clip, immediately before their first oocyte retrieval. MAIN RESULTS AND THE ROLE OF CHANCE The video clip did not affect women’s anxiety on the day of oocyte retrieval (mean STAI-State score intervention group = 42.7 ± 8.1 vs control group = 42.1 ± 8.5, P = 0.68). Men who watched the video clip were, however, significantly less anxious than men who did not watch it (35.8 (±6.4) vs 38.2 (±7.6), P = 0.034). Surprisingly, infertility-specific distress was higher among women and men who watched the video clip, as compared to women and men who did not watch the video clip (mean Infertility-specific Distress (IDS) scale score for women, 25.8 (±4.9) vs 24.3 (±4.6), P = 0.051; men, 22.6 (±5.0) vs 20.8 (±4.7), P = 0.023). The QPE clarified that watching the video clip did not increase knowledge about what would happen but that some women and men found the visualization of invasive procedural steps more confrontational than the earlier received, abstract, written, and verbal information. All but one woman and all men in the intervention group would recommend th","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"127 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143575266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atosiban in individuals with previous implantation failure undergoing frozen blastocyst transfer: a randomized controlled trial","authors":"He Cai, Shan Liu, Wentao Li, Haiyan Bai, Hanying Zhou, Xia Xue, Wei Li, Mingzhao Li, Xiaoli Zhao, Chun Ma, Hui Wang, Li Tian, Tao Wang, Na Li, Jinlin Xie, Lijuan Chen, Min Wang, Chen Yang, Hua Jia, Dian Zhang, Danmeng Liu, Ben W Mol, Juanzi Shi","doi":"10.1093/humrep/deaf035","DOIUrl":"https://doi.org/10.1093/humrep/deaf035","url":null,"abstract":"STUDY QUESTION Does the intravenous administration of Atosiban around the time of frozen blastocyst transfer to reduce uterine contractility increase the likelihood of live birth in individuals undergoing ART treatment? SUMMARY ANSWER In individuals with a history of one previous implantation failure, Atosiban did not significantly increase the live birth rates following frozen blastocyst transfer. WHAT IS KNOWN ALREADY Excessive uterine contraction waves during the embryo transfer procedure have been associated with decreased pregnancy rates. Atosiban, an oxytocin receptor antagonist, could reduce uterine contractions and potentially enhance implantation success in ART. However, data are inconclusive. STUDY DESIGN, SIZE, DURATION This study is a randomized, controlled, single-center, randomized, placebo-controlled clinical trial. Recruitment was from July 2019 to June 2023, with follow-up until May 2024. Participants, treating clinicians and embryologists were blinded to group assignment. Participants were randomized in a 1:1 ratio to receive intravenous Atosiban (37.5 mg) (n = 549) or placebo 30 min (n = 551) before the transfer procedure. PARTICIPANTS/MATERIALS, SETTING, METHODS Eleven hundred individuals scheduled for single frozen blastocyst transfer who had previously experienced one episode of implantation failure during ART. Uterine contractility was assessed via transvaginal ultrasound before administering the assigned intervention. The primary outcome was live birth. A pre-specified subgroup analysis was performed in individuals with and without abnormal uterine contractions. MAIN RESULTS AND THE ROLE OF CHANCE Of the 1100 randomized participants (mean age, 31 years), 1099 (99.9%) were assessed for the primary outcomes, with the exception of one participant in the placebo group who was lost to follow-up after clinical pregnancy. Live birth occurred in 272/549 (49.5%) in the Atosiban group and 246/550 (44.7%) in the placebo group (absolute difference 4.8%, 95% CI −1.1 to 10.7; risk ratio [RR] 1.11, 95% CI 0.98 to 1.26; P = 0.10). Uterine contractility was evaluated in 720 participants (65% of the total cohort). Among them, 163 participants (23%) with abnormal contractions had live birth rates of 51.9% and 39.3% in the Atosiban and placebo groups, respectively (absolute difference 12.6%, 95% CI −2.6 to 27.8; RR 1.32, 95% CI 0.94 to 1.86; P = 0.11). LIMITATIONS, REASONS FOR CAUTION The study’s findings may not be widely applicable due to its single-center design, subjective video assessments, and focus on a specific subset of individuals experiencing failed embryo implantation, potentially introducing biases and confounding factors. Additionally, the limited examination of uterine contractions in only 65% of participants and the absence of re-evaluation due to resource constraints restrict the study’s analytical power and the confirmation of Atosiban’s effectiveness. WIDER IMPLICATIONS OF THE FINDINGS Our study shows do not support the rou","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":"16 1","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143546156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective associations of adolescent obesity phenotypes with self-reported polycystic ovary syndrome diagnosis in young adulthood.","authors":"L A Reich, R G St Fleur, A Gjelsvik, A E Field, H N Ziobrowski","doi":"10.1093/humrep/deae294","DOIUrl":"10.1093/humrep/deae294","url":null,"abstract":"<p><strong>Study question: </strong>Are empirically derived adolescent overweight/obesity phenotypes differentially associated with polycystic ovary syndrome (PCOS) in young adulthood?</p><p><strong>Summary answer: </strong>Self-reported PCOS diagnosis risk in young adulthood varied by empirically derived adolescent overweight/obesity phenotypes, with the highest risk observed among those in the 'mothers with obesity' and 'early puberty' phenotypes.</p><p><strong>What is known already: </strong>Overweight and obesity during puberty are postulated to promote the development of PCOS. Much of the prior literature in this area is cross-sectional and defines weight status based solely on BMI, yet emerging research suggests that not all people with overweight/obesity have the same risk for chronic health conditions, including PCOS.</p><p><strong>Study design, size, duration: </strong>Data came from 4838 female participants in the Growing Up Today Study (GUTS), an ongoing prospective cohort study in the USA that has followed children aged 9-14 into young adulthood (ages 31-37, with 16 waves of data collection between 1996 and 2019).</p><p><strong>Participants/materials, settings, methods: </strong>We previously used latent class analysis to empirically derive obesity phenotypes among 2038 female participants aged 14-19 years with overweight/obesity in the sample, as determined by participants' self-reported height and weight status. Indicators in the latent class analysis were participants' maternal weight status, disordered eating behaviors, body image and weight concerns, depressive symptoms and pubertal timing. The derived obesity phenotypes included 'mothers with obesity', 'early puberty', 'high weight concerns', and 'mixed'. Among these participants and female participants without adolescent overweight/obesity, we used logistic regression with generalized estimating equations to examine associations of adolescent obesity phenotypes with self-reported PCOS diagnosis after age 19. Analyses were adjusted for potential confounders.</p><p><strong>Main results and the role of chance: </strong>Participants in all four obesity phenotypes were more likely than participants without overweight/obesity to report a PCOS diagnosis ('mothers with obesity' phenotype: odds ratio (OR) = 4.50, 95% CI = 2.61, 7.77; 'early puberty' phenotype: OR = 2.51, 95% CI = 1.59, 3.97; 'high weight concerns' phenotype: OR = 2.01, 95% CI = 1.24, 3.24; 'mixed' phenotype: OR = 1.94, 95% CI = 1.33, 2.82). Individuals in the 'mothers with obesity' phenotype had a significantly greater risk of PCOS diagnosis compared to those in the 'mixed' and 'high weight concerns' phenotypes (P < 0.05).</p><p><strong>Limitations, reasons for caution: </strong>Participants self-reported PCOS diagnosis, which may underestimate new-onset PCOS and limit our ability to establish a temporal order between overweight/obesity and PCOS development. Residual confounding may also explain some of the observed ass","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":"545-552"},"PeriodicalIF":6.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Unveiling early predictors of adverse birth outcomes: the potential and limits of embryonic growth metrics.","authors":"Jorine Roelants, Marijn J Vermeulen, Régine Steegers-Theunissen","doi":"10.1093/humrep/deae296","DOIUrl":"10.1093/humrep/deae296","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":"563-564"},"PeriodicalIF":6.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethical considerations on surrogacy†.","authors":"Francoise Shenfield, Basil Tarlatzis, Guiliana Baccino, Theofano Bounartzi, Lucy Frith, Guido Pennings, Veerle Provoost, Nathalie Vermeulen, Heidi Mertes","doi":"10.1093/humrep/deaf006","DOIUrl":"10.1093/humrep/deaf006","url":null,"abstract":"<p><p>Surrogacy is the assisted reproductive technology (ART) practice in which a person becomes pregnant, carries, and delivers a child on behalf of another couple/person, who are the intended parent(s). Surrogacy is an especially complex practice as the interests of the intended parents, the gestational carrier, and the future child may differ. This paper considers ethical questions related to different forms of surrogacy. It concludes that non-commercial surrogacy is an acceptable method of assisted reproduction for specific indications. When using surrogacy to form a family, it is essential that there are measures to protect all parties, to guarantee well-considered decision-making, and to minimize risks. The current paper formulates recommendations to promote these measures. This paper is an update to the ESHRE Task Force Ethics and Law Paper 10: Surrogacy and replaces this paper.</p>","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":"420-425"},"PeriodicalIF":6.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human ovarian tissue xenotransplantation: advancements, challenges, and future perspectives.","authors":"Paweena Thuwanut, Ellen C R Leonel, Thalles Fernando Rocha Ruiz, Porntip Sirayapiwat, Stine Gry Kristensen, Christiani A Amorim","doi":"10.1093/humrep/deae291","DOIUrl":"10.1093/humrep/deae291","url":null,"abstract":"<p><p>Ovarian tissue cryopreservation and transplantation has emerged as a promising fertility preservation technique for individuals facing premature ovarian insufficiency due to various medical conditions or treatments. Xenotransplantation, involving the transplantation of ovarian tissue into animal hosts, has played a pivotal role in refining ovarian tissue cryopreservation and transplantation techniques and addressing key challenges. This review provides a comprehensive overview of the current landscape of ovarian tissue xenotransplantation research, focusing on its applications in investigating ovarian biology, optimizing ovarian tissue cryopreservation and transplantation protocols, and assessing safety concerns. It also explores the utilization of xenografting of human ovarian tissue in mouse models in the last 10 years. Key findings from preclinical studies investigating grafting site optimization, cryopreservation protocol refinement, the development of strategies to mitigate chemotherapy-induced damage, follicle development, tissue revascularization, and the risk of malignant cell reintroduction are summarized. Moreover, the review examines the ethical considerations surrounding the use of animals in ovarian tissue xenotransplantation research and suggests emerging alternative models that aim to minimize animal use while maximizing clinical relevance.</p>","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":"410-419"},"PeriodicalIF":6.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling early predictors of adverse birth outcomes: the potential and limits of embryonic growth metrics.","authors":"Binglin Li, Yueqi Feng, Ruijuan Chen","doi":"10.1093/humrep/deae295","DOIUrl":"10.1093/humrep/deae295","url":null,"abstract":"","PeriodicalId":13003,"journal":{"name":"Human reproduction","volume":" ","pages":"561-562"},"PeriodicalIF":6.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}